More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

This study reveals that the chemical nature of covalent warheads in BTK inhibitors, specifically 2-butynamide versus acrylamide, actively modulates protein conformational dynamics and signaling efficacy rather than serving merely as inert attachment groups, thereby influencing inhibitor performance and potential resistance mechanisms.

The Gist

Imagine your body has a security guard named BTK. This guard's job is to stand at a gate and stop a specific signal (called PLCgamma) from passing through, which helps keep your immune system from going haywire.

For years, scientists have been designing "handcuffs" (medicines) to grab this guard and stop him from working. These handcuffs have a special sticky tip called a warhead that chemically bonds to the guard so he can't escape. The two most common types of sticky tips used are like Velcro (called acrylamide) and a super-strong glue (called 2-butynamide).

Scientists used to think these sticky tips were just simple tools: they grab the guard, and that's it. They assumed the type of glue didn't change how the guard acted once he was caught; they thought the guard would just stand there, frozen, no matter which glue was used.

But this paper found out that assumption was wrong.

Here is what the researchers discovered using four different "handcuffs" (Tirabrutinib, Acalabrutinib, Ibrutinib, and Zanubrutinib):

1. The "Velcro" Handcuffs (Ibrutinib & Zanubrutinib): When these grab the BTK guard, they lock him up tight and still. He becomes a statue. He can't move, and he can't let the signal (PLCgamma) through. He does his job perfectly at stopping the signal.
2. The "Super-Glue" Handcuffs (Tirabrutinib & Acalabrutinib): Even though these also grab the guard permanently, they don't freeze him in place. Instead, they leave him wiggling and shaking. The guard is stuck to the handcuff, but his body is still flopping around in different positions.
3. The Problem with Wiggling: Because the guard is wiggling, he actually gets better at grabbing the signal (PLCgamma) and letting it through, even though he is technically "caught." This means the "Super-Glue" handcuffs are actually less effective at stopping the signal than the "Velcro" ones.

The "Magic Switch" Experiment:
To prove it was the sticky tip causing the problem, the scientists took the body of the "Velcro" handcuff and swapped its tip for the "Super-Glue" tip. Suddenly, the handcuff started making the guard wiggle and became less effective. They did the reverse, too: swapping the "Super-Glue" tip for "Velcro" made the guard freeze and work better.

The Big Takeaway:
The part of the medicine that was supposed to be just a simple "sticky hook" is actually acting like a remote control. Depending on which hook you use, it changes the guard's personality and movements. This means that even if two medicines seem to do the same thing (grab the target), they might work very differently because of how they change the target's shape and behavior. This could explain why some medicines stop working (resistance) while others keep working, even if they look similar on paper.

Technical Summary

Problem
Covalent inhibitors have become a standard therapeutic approach for various diseases, relying on reactive electrophiles, known as warheads, to bind irreversibly to target proteins. Cysteine-targeting electrophiles, specifically acrylamide and 2-butynamide, are the most prevalent warheads used in this context. These moieties are traditionally selected for their efficiency and selectivity in modifying the target protein, operating under the prevailing assumption that they are functionally inert once the covalent bond is formed, serving merely as an attachment module without influencing the protein's broader dynamics or function.

Methodology
The study utilized a panel of four clinically relevant Bruton's tyrosine kinase (BTK) covalent inhibitors: Tirabrutinib, Acalabrutinib, Ibrutinib, and Zanubrutinib. These compounds were compared based on their warhead chemistry, specifically contrasting those bearing the 2-butynamide warhead (Tirabrutinib and Acalabrutinib) against those with the acrylamide warhead (Ibrutinib and Zanubrutinib). To investigate the functional consequences of these warheads, the researchers examined the conformational states of BTK upon inhibitor binding, assessed the dynamic exchange between these states, and measured binding affinity to the substrate PLC$\gamma$. Furthermore, the efficacy of signaling inhibition was evaluated. A critical experimental component involved swapping the warheads between Tirabrutinib and Ibrutinib to isolate the specific effects of the electrophile from the rest of the inhibitor scaffold.

Key Contributions and Results
The study challenges the assumption that covalent warheads are functionally inert. The results demonstrate that the 2-butynamide warhead found in Tirabrutinib and Acalabrutinib induces significant conformational heterogeneity in key regions of BTK required for signaling. Unlike the BTK bound by Ibrutinib or Zanubrutinib, the BTK complexes formed with 2-butynamide-containing inhibitors adopt multiple conformational states that exist in dynamic exchange.

Functionally, this conformational heterogeneity correlates with distinct biological outcomes:

• BTK bound to Tirabrutinib or Acalabrutinib exhibits increased binding to the substrate PLC$\gamma$.
• Despite this increased substrate binding, these inhibitors are less effective at inhibiting PLC$\gamma$ signaling compared to Ibrutinib.
• The warhead swap experiment confirmed that the observed differences in BTK dynamics and inhibitor efficacy are directly attributable to the warhead structure; swapping the warheads between Tirabrutinib and Ibrutinib resulted in a corresponding switch in the protein's dynamic behavior and inhibitory potency.

Significance
The paper establishes that covalent warheads exert unanticipated, specific allosteric effects on their target proteins, influencing conformational dynamics and functional output beyond simple covalent attachment. This finding suggests that the choice of warhead is a critical determinant of inhibitor mechanism and efficacy. Consequently, these warhead-specific allosteric effects may provide a mechanistic basis for understanding inhibitor-specific resistance patterns, offering a new perspective on how covalent inhibitors interact with their targets in a therapeutic context.